Buprenorphine alone and in combination with naloxone in non-dependent humans

Linda L. Weinhold, Kenzie L. Preston, Magi Farre, Ira A. Liebson, George Bigelow

Research output: Contribution to journalArticle

Abstract

This study evaluated the effects of concurrent naloxone on the opioid agonist effects of buprenorphine, a mixed agonistantagonist marketed as an analgesic and under development as a treatment for drug abuse. In a residential laboratory seven non-physically-dependent opioid abuser volunteers received intramuscular buprenorphine (0.4 mg or 0.8 mg/70 kg) alone and in combination with naloxone (0.4 mg or 0.8 mg/70 kg) versus placebo. Buprenorphine produced dose-related opioid agonist effects on physiological and subjective measures. Concurrent naloxone attenuated the opioid agonist effects of buprenorphine. Thus, a combination product of buprenorphine and naloxone may have lower abuse liability than buprenorphine alone.

Original languageEnglish (US)
Pages (from-to)263-274
Number of pages12
JournalDrug and Alcohol Dependence
Volume30
Issue number3
DOIs
StatePublished - 1992

Fingerprint

Buprenorphine
Naloxone
Opioid Analgesics
drug abuse
liability
abuse
Substance-Related Disorders
Analgesics
Volunteers
Placebos
Pharmaceutical Preparations

Keywords

  • abuse liability
  • buprenorphine
  • human
  • naloxone
  • opioid

ASJC Scopus subject areas

  • Medicine(all)
  • Behavioral Neuroscience
  • Toxicology
  • Health(social science)

Cite this

Buprenorphine alone and in combination with naloxone in non-dependent humans. / Weinhold, Linda L.; Preston, Kenzie L.; Farre, Magi; Liebson, Ira A.; Bigelow, George.

In: Drug and Alcohol Dependence, Vol. 30, No. 3, 1992, p. 263-274.

Research output: Contribution to journalArticle

Weinhold, Linda L. ; Preston, Kenzie L. ; Farre, Magi ; Liebson, Ira A. ; Bigelow, George. / Buprenorphine alone and in combination with naloxone in non-dependent humans. In: Drug and Alcohol Dependence. 1992 ; Vol. 30, No. 3. pp. 263-274.
@article{e97766019466423cae5fb96de54782d2,
title = "Buprenorphine alone and in combination with naloxone in non-dependent humans",
abstract = "This study evaluated the effects of concurrent naloxone on the opioid agonist effects of buprenorphine, a mixed agonistantagonist marketed as an analgesic and under development as a treatment for drug abuse. In a residential laboratory seven non-physically-dependent opioid abuser volunteers received intramuscular buprenorphine (0.4 mg or 0.8 mg/70 kg) alone and in combination with naloxone (0.4 mg or 0.8 mg/70 kg) versus placebo. Buprenorphine produced dose-related opioid agonist effects on physiological and subjective measures. Concurrent naloxone attenuated the opioid agonist effects of buprenorphine. Thus, a combination product of buprenorphine and naloxone may have lower abuse liability than buprenorphine alone.",
keywords = "abuse liability, buprenorphine, human, naloxone, opioid",
author = "Weinhold, {Linda L.} and Preston, {Kenzie L.} and Magi Farre and Liebson, {Ira A.} and George Bigelow",
year = "1992",
doi = "10.1016/0376-8716(92)90061-G",
language = "English (US)",
volume = "30",
pages = "263--274",
journal = "Drug and Alcohol Dependence",
issn = "0376-8716",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Buprenorphine alone and in combination with naloxone in non-dependent humans

AU - Weinhold, Linda L.

AU - Preston, Kenzie L.

AU - Farre, Magi

AU - Liebson, Ira A.

AU - Bigelow, George

PY - 1992

Y1 - 1992

N2 - This study evaluated the effects of concurrent naloxone on the opioid agonist effects of buprenorphine, a mixed agonistantagonist marketed as an analgesic and under development as a treatment for drug abuse. In a residential laboratory seven non-physically-dependent opioid abuser volunteers received intramuscular buprenorphine (0.4 mg or 0.8 mg/70 kg) alone and in combination with naloxone (0.4 mg or 0.8 mg/70 kg) versus placebo. Buprenorphine produced dose-related opioid agonist effects on physiological and subjective measures. Concurrent naloxone attenuated the opioid agonist effects of buprenorphine. Thus, a combination product of buprenorphine and naloxone may have lower abuse liability than buprenorphine alone.

AB - This study evaluated the effects of concurrent naloxone on the opioid agonist effects of buprenorphine, a mixed agonistantagonist marketed as an analgesic and under development as a treatment for drug abuse. In a residential laboratory seven non-physically-dependent opioid abuser volunteers received intramuscular buprenorphine (0.4 mg or 0.8 mg/70 kg) alone and in combination with naloxone (0.4 mg or 0.8 mg/70 kg) versus placebo. Buprenorphine produced dose-related opioid agonist effects on physiological and subjective measures. Concurrent naloxone attenuated the opioid agonist effects of buprenorphine. Thus, a combination product of buprenorphine and naloxone may have lower abuse liability than buprenorphine alone.

KW - abuse liability

KW - buprenorphine

KW - human

KW - naloxone

KW - opioid

UR - http://www.scopus.com/inward/record.url?scp=0026658251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026658251&partnerID=8YFLogxK

U2 - 10.1016/0376-8716(92)90061-G

DO - 10.1016/0376-8716(92)90061-G

M3 - Article

C2 - 1396108

AN - SCOPUS:0026658251

VL - 30

SP - 263

EP - 274

JO - Drug and Alcohol Dependence

JF - Drug and Alcohol Dependence

SN - 0376-8716

IS - 3

ER -